Metabolically-inactive glucagon-like peptide-1(9–36)amide confers selective protective actions against post-myocardial infarction remodelling

Glucagon-like peptide-1 (GLP-1) therapies are routinely used for glycaemic control in diabetes and their emerging cardiovascular actions have been a major recent research focus. In addition to GLP-1 receptor a...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Source Type: research

Related Links:

The current study assessed associations of clinical characteristics and all-cause mortality among a cohort of Veterans initiating pain services. Analyses were also stratified by age to examine potential variations. Demographic (male, age), medical comorbidities (diabetes, myocardial infarction, chronic pulmonary conditions, cancer, renal disease, liver disease), pain characteristics (pain intensity, opioid analgesic prescription), and mental health characteristics (depression, opioid use disorder, opioid poisoning/suicide attempts) were extracted from Veterans Health Administration records.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research
Zoltan Kiss, Gy örgy Rokszin, Zsolt Abonyi-Tóth, György Jermendy, Péter Kempler, István Wittmann
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Publication date: Available online 20 March 2019Source: Canadian Journal of CardiologyAuthor(s): Lucas C. Godoy, Patrick R. Lawler, Michael E. Farkouh, Bronwyn Hersen, José C. Nicolau, Vivek RaoAbstractThe prevalence of diabetes mellitus (DM) is rising globally and in Canada. Besides being a risk factor for the development of coronary artery disease, DM is also a marker of poor prognosis in patients with acute coronary syndrome (ACS), increasing the risks for both ischemic and bleeding complications. Patients with DM have a high prevalence of multivessel coronary artery disease (MVD) and robust evidence has supporte...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
This study effectively shows that by giving health consumers the tools they need to better manage their health, we can empower them to live healthier lives,” senior study author and chief medical officer Dr. Bimal Shah said in a prepared statement. Read more  Neovasc presents Reducer data Neovasc (NSDQ:NVCN) said today that it released data on its Neovasc Reducer device during the American College of Cardiology’s 68th Annual Scientific Sessions in New Orleans. During the session, researchers explored the treatment of refractory angina in patients with no options, Vancouver-based Neovasc said, tou...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Assist Devices Cardiovascular Clinical Trials Featured Patient Monitoring ReCor Medical Source Type: news
(CNN) — If you’re a healthy older adult looking for ways to reduce your risk of heart attack and stroke, don’t turn to that age-old standby: daily low-dose aspirin. It’s no longer recommended as a preventative for older adults who don’t have a high risk or existing heart disease, according to guidelines announced Sunday by the American College of Cardiology and the American Heart Association. “For the most part, we are now much better at treating risk factors such as hypertension, diabetes and especially high cholesterol,” said North Carolina cardiologist Dr. Kevin Campbell, who wa...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News aspirin CNN Source Type: news
CONCLUSIONS: Patients with T2DM and prior MI are at high risk of MACE and CV death/HHF. Dapagliflozin appears to robustly reduce the risk of both composite outcomes in these patients. Future studies should aim to confirm the large clinical benefits with SGLT2i we observed in patients with prior MI. CLINICAL TRIAL REGISTRATION: URL: Unique Identifier: NCT01730534. PMID: 30882239 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
This article is part of a Special Issue entitled: Cardiomyocyte biology: new pathways of differentiation and regeneration edited by Marijke Brinkm, Marcus C. Schaub, and Christian Zuppinger.
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - Category: Molecular Biology Source Type: research
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial was sponsored by the New York University School of Medicine. Collaborators include National Heart, Lung, and Blood Institute (NHLBI), Stanford University, Duke University, Emory University, Harvard University and several other leading institutions. ISCHEMIA trial randomized 5179 patients with stable ischemic heart disease with moderate to severe degree of inducible ischemia on stress testing. Blinded CT coronary angiogram was used to exclude those with significant unprotected left main coronary artery disease or ...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardiology Source Type: blogs
mberly Sullivan Prevalence of nine chronic medical conditions in the population-based Ft. Devens Cohort (FDC) of GW veterans were compared with the population-based 2013–2014 National Health and Nutrition Examination Survey (NHANES) cohort. Excess prevalence was calculated as the difference in prevalence estimates from the Ft. Devens and NHANES cohorts; and confidence intervals and p-values are based on the standard errors for the two prevalence estimates. FDC males were at increased risk for reporting seven chronic medical conditions compared with NHANES males. FDC females were at decreased risk for high blo...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations Phase 3 Study Will Enroll High-Risk Patients who Have Significant Atherosclerotic Disease or Diabetes and are at High Risk for a First Cardiovascular Event THOUSAND OAKS, Calif., March 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to conduct VESALIUS-CV, a multinational clinical outcomes study for Repatha® (evolocumab) which will involve at least 13,000 patients worldwide at high risk of experiencing a first cardiovascular (CV) event, despite optimiz...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Heart | Heart Attack